Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ranbaxy Bids For Merck Generics Arm

March 19, 2007 | A version of this story appeared in Volume 85, Issue 12

New Delhi-based Ranbaxy Laboratories confirms that it has put in a bid to acquire the generic pharmaceuticals business of Merck KGaA. Ranbaxy says it was compelled to comment on rumors of its interest in the unit in order to deny that its offer is worth as much as $6 billion. The $6 billion figure appearing in media reports is "incorrect and speculative," Ranbaxy says. Merck is selling the business to help pay for its acquisition of Serono, the Swiss biotech company. Merck's generics business reported sales of $2.3 billion in 2006.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.